Want to see TSE:NRX full AI Analyst Report?
Total Valuation
NurExone Biologic has a market cap or net worth of C$38.87M. The enterprise value is C$49.36M.
Market CapC$38.87M
Enterprise ValueC$49.36M
Share Statistics
NurExone Biologic has 77,746,750 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding77,746,750
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
NurExone Biologic’s return on equity (ROE) is -2.31 and return on invested capital (ROIC) is -201.88%.
Return on Equity (ROE)-2.31
Return on Assets (ROA)-1.56
Return on Invested Capital (ROIC)-201.88%
Return on Capital Employed (ROCE)-2.04
Revenue Per Employee0.00
Profits Per Employee-375.53K
Employee Count17
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of NurExone Biologic is ―. NurExone Biologic’s PEG ratio is -1.72.
PE Ratio―
PS Ratio0.00
PB Ratio13.94
Price to FCF-8.42
Price to Operating Cash Flow-6.82
PEG Ratio-1.72
Income Statement
In the last 12 months, NurExone Biologic had revenue of 0.00 and earned -6.38M in profits. Earnings per share was -0.08.
Revenue0.00
Gross Profit0.00
Operating Income-6.32M
Pretax Income-6.38M
Net Income-6.38M
EBITDA-6.17M
Earnings Per Share (EPS)-0.08
Cash Flow
In the last 12 months, operating cash flow was -4.65M and capital expenditures -57.00K, giving a free cash flow of -4.71M billion.
Operating Cash Flow-4.65M
Free Cash Flow-4.71M
Free Cash Flow per Share-0.06
Dividends & Yields
NurExone Biologic pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.13
52-Week Price Change-31.43%
50-Day Moving Average0.60
200-Day Moving Average0.59
Relative Strength Index (RSI)36.69
Average Volume (3m)12.64K
Important Dates
NurExone Biologic upcoming earnings date is Nov 20, 2026, TBA (Confirmed).
Last Earnings DateAug 31, 2026
Next Earnings DateNov 20, 2026
Ex-Dividend Date―
Financial Position
NurExone Biologic as a current ratio of 2.63, with Debt / Equity ratio of 4.11%
Current Ratio2.63
Quick Ratio2.63
Debt to Market Cap0.00
Net Debt to EBITDA0.33
Interest Coverage Ratio-203.97
Taxes
In the past 12 months, NurExone Biologic has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
NurExone Biologic EV to EBITDA ratio is -5.91, with an EV/FCF ratio of -7.98.
EV to Sales0.00
EV to EBITDA-5.91
EV to Free Cash Flow-7.98
EV to Operating Cash Flow-8.07
Balance Sheet
NurExone Biologic has C$1.01M in cash and marketable securities with C$52.00K in debt, giving a net cash position of C$954.00K billion.
Cash & Marketable SecuritiesC$1.01M
Total DebtC$52.00K
Net CashC$954.00K
Net Cash Per ShareC$0.01
Tangible Book Value Per ShareC$0.03
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for NurExone Biologic is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast19.02%